Medtech startup Innovodigm raises Rs 5.5 crore in a seed funding round

Medtech startup Innovodigm has raised Rs 5.5 crore in a seed funding round led by the Indian Angel Network (IAN), which invested Rs 4.5 crore, with the remainder invested by PadUp Ventures. 

The capital will support process optimization, infrastructure scale-up, and team expansion as the startup prepares for third-party preclinical validation and clinical trials, Innovodigm said in a press statement.

Founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm is developing a proprietary Microneedle Array Patch (MAP) platform—a needle-free, thermostable method of vaccine delivery aimed at addressing limitations in traditional injectable immunization. Unlike conventional cold-chain dependent vaccines, Innovodigm’s micro-array patches contain thermostabilized vaccines that remain viable for up to 120 days at 40°C. This innovation could drastically reduce cold-storage requirements and medical waste while improving access in underserved regions.

The startup's technology has garnered early institutional validation. Its MAP platform was selected as a Top 2 Technology at the Nano Electronics Showcase 2025 organized by the Ministry of Electronics and IT. Innovodigm has also signed a Material Transfer Agreement (MTA) with an Indian vaccine manufacturer to conduct third-party validation, with clinical trials expected to commence in 2026.

A spinout from IIT Kharagpur’s Microelectronics and MEMS Lab, Innovodigm positions itself at the intersection of biomedical engineering and public health, with a focus on scalable, low-cost immunization delivery for both domestic and international markets. The startup plans to adapt its MAP for a wide range of vaccines including measles, hepatitis, influenza, and COVID-19 boosters.

As part of its long-term strategy, Innovodigm aims to build decentralized manufacturing hubs to localize production and reduce distribution bottlenecks—especially in low- and middle-income countries.